PMID- 23763082
OWN - NLM
STAT- MEDLINE
DCOM- 20130710
LR  - 20181203
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 91
IP  - 4
DP  - 2013 Apr
TI  - Luliconazole for the treatment of interdigital tinea pedis: A double-blind, 
      vehicle-controlled study.
PG  - 203-10
AB  - Tinea pedis (TP) typically is treated with topical antifungal agents. 
      Luliconazole, a novel imidazole drug, is shown to be as or more effective in 
      vitro and in vivo than bifonazole, terbinafine, and lanoconazole. Two treatment 
      durations with luliconazole cream 1% were evaluated for treatment of TP. 
      Participants with interdigital TP were randomized (N= 147) and treated with 
      either luliconazole or its vehicle for either 2 or 4 weeks. The primary efficacy 
      end point was the proportion of participants achieving complete clearance 2 weeks 
      following completion of treatment. In the 2-week active treatment group, complete 
      clearance was achieved in 26.8% (11/41) of participants versus 9. 1% (2/22) in 
      the 2-week vehicle group at 2-weeks posttreatment. In the 4-week active treatment 
      group, 45.7% (16/35) achieved complete clearance versus 10.0% (2/20) in the 
      4-week vehicle group at 2-weeks posttreatment. Twenty-three adverse events (AEs) 
      were reported; most were mild (56.5% [13/23]) to moderate (26. 1% [6/23]) in 
      severity. All reported AEs were determined to be unrelated (78.3% [18/23]) or 
      unlikely related (21.7% [5/23]) to the study medication. The results of this 
      study indicate that luliconazole cream 1% applied once daily for either 2 or 4 
      weeks is safe and effective for treatment of TP. More importantly, the antifungal 
      effects of luliconazole persist for several weeks, resulting in increased rates 
      of mycological cure.
FAU - Jarratt, Michael
AU  - Jarratt M
AD  - DermResearch Inc, Austin, Texas, USA.
FAU - Jones, Terry
AU  - Jones T
FAU - Kempers, Steven
AU  - Kempers S
FAU - Rich, Phoebe
AU  - Rich P
FAU - Morton, Katy
AU  - Morton K
FAU - Nakamura, Norifumi
AU  - Nakamura N
FAU - Tavakkol, Amir
AU  - Tavakkol A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Antifungal Agents)
RN  - 0 (Imidazoles)
RN  - RE91AN4S8G (luliconazole)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antifungal Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Imidazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Tinea Pedis/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/06/15 06:00
MHDA- 2013/07/11 06:00
CRDT- 2013/06/15 06:00
PHST- 2013/06/15 06:00 [entrez]
PHST- 2013/06/15 06:00 [pubmed]
PHST- 2013/07/11 06:00 [medline]
PST - ppublish
SO  - Cutis. 2013 Apr;91(4):203-10.